10-Q: Anixa Biosciences Reports Reduced Losses, Advances Cancer Trials

Anixa Biosciences' latest 10-Q filing reveals a significant reduction in net loss and operating expenses, alongside promising clinical progress in its cancer vaccine and CAR-T therapy programs.

Summary

• Net loss attributable to common shareholders decreased to $2.258 million for the three months ended July 31, 2025, from $3.277 million in the prior year period.
• For the nine months ended July 31, 2025, net loss attributable to common shareholders decreased to $8.232 million, compared to $9.671 million in the same period last year.
• Research and development expenses decreased by $870,000 to $1.055 million for the three months, and by $991,000 to $3.929 million for the nine months ended July 31, 2025.
• General and administrative expenses decreased by $286,000 to $1.381 million for the three months, and by $852,000 to $4.896 million for the nine months ended July 31, 2025.
• Cash, cash equivalents, and short-term investments totaled $16.029 million as of July 31, 2025, a decrease of $3.895 million from October 31, 2024.
• The company believes its current liquidity is sufficient to fund operations for significantly longer than 12 months from September 10, 2025.
• Progress continues in the Phase 1 CAR-T therapy trial for ovarian cancer, with the fourth dose cohort (30x higher dose) treated from June 2025 through September 10, 2025, showing well-tolerated treatment and anecdotal signs of efficacy.
• Enrollment and treatment are complete for the Phase 1 breast cancer vaccine trial, with final data anticipated at the San Antonio Breast Cancer Symposium in December 2025.
• A new vaccine discovery program for lung, colon, and prostate cancers is underway through a joint development agreement with Cleveland Clinic.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to significant reductions in net loss and operating expenses, coupled with consistent and promising clinical trial progress for both CAR-T and vaccine programs. The company's liquidity position is also stated as sufficient for over 12 months. However, the continued pre-revenue status and reliance on future licensing for profitability temper the overall sentiment.

Positives

• Net loss significantly decreased for both the three and nine-month periods ended July 31, 2025, indicating improved financial efficiency.
• Operating expenses, including R&D and G&A, saw substantial reductions, reflecting effective cost management.
• The CAR-T therapy for ovarian cancer continues to advance through dose-escalation, with all dose cohorts, including the highest (30x), being well-tolerated by patients.
• Anecdotal signs of efficacy, such as T cell infiltration and tumor necrosis, have been observed in multiple CAR-T patients, with one patient surviving two years post-initial treatment and receiving re-dosing approval from the FDA.
• The breast cancer vaccine Phase 1 trial has completed enrollment and treatment, with promising immunological data presented showing antigen-specific T cell responses across all dose levels and patient groups.
• The ovarian cancer vaccine technology is being developed with significant scientific and financial resources from the NCI's PREVENT program, requiring no material financial expenditures from Anixa.
• The company has sufficient cash, cash equivalents, and short-term investments to fund operations for significantly longer than 12 months, providing a stable financial runway.

Negatives

• The company continues to report no revenue from its therapeutics or vaccine programs, indicating a pre-commercial stage with no immediate path to profitability.
• Cash, cash equivalents, and short-term investments decreased by $3.895 million over the nine months, reflecting ongoing cash burn from operations.
• Interest income decreased due to a reduction in short-term investments and lower interest rates, impacting non-operating income.
• The accumulated deficit increased to $248.982 million, highlighting the cumulative losses incurred by the company to date.

Risks

• No material changes in risk factors from those disclosed in the Annual Report on Form 10-K for the fiscal year ended October 31, 2024 were reported in this filing.

Future Outlook

The company does not expect to generate revenue from its current vaccine or therapy programs in the near term, anticipating that eventual profitability will come from licensing its technologies to large pharmaceutical companies. This licensing process is expected to take several years and is contingent on positive human clinical trial results. Management believes existing cash, cash equivalents, and short-term investments are sufficient to fund activities for significantly longer than 12 months from September 10, 2025.

Management Comments

• "We do not expect to begin generating revenue with respect to any of our current vaccine or therapy programs in the near term."
• "We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as vaccines or therapeutics."
• "The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials."
• "Based on currently available information as of September 10, 2025, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our activities for at least the next twelve months."
• "Therefore, the Company believes that it has sufficient cash, cash equivalents and short-term investments to operate its business, as currently contemplated, for significantly longer than 12 months from the date of this Report."

Industry Context

Anixa Biosciences operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oncology therapeutics and vaccines. The company's strategy of collaborating with institutions like The Wistar Institute, Moffitt Cancer Center, and Cleveland Clinic, and leveraging programs like NCI's PREVENT, is a common approach for smaller biotechs to conserve capital and de-risk development. The focus on unmet needs in ovarian and triple-negative breast cancer, as well as new vaccine discovery, aligns with significant areas of ongoing research and investment in the broader oncology industry. The reliance on future licensing deals for commercialization is typical for pre-revenue biotech firms.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks.

Legal Proceedings

• Other than lawsuits related to the enforcement of patent rights, the company is not a party to any material pending legal proceedings, nor is it aware of any pending litigation or legal proceeding against it that would have a material adverse effect on its results of operations or financial condition.

Related Party Transactions

• Wistar's equity stake in Certainty Therapeutics, a subsidiary, was 4.1% as of July 31, 2025, subject to dilution by further company funding.

Stakeholder Impact

• Shareholders: Potential for future dilution from the remaining $95 million ATM offering capacity, but also potential upside from positive clinical trial results and eventual licensing deals.
• Patients: Continued progress in clinical trials offers hope for new therapeutic and preventative options for ovarian and breast cancers, as well as future cancer types.
• Employees and Directors: Stock-based compensation remains a component of their remuneration, aligning incentives with company performance.
• Creditors: The company's improved liquidity and reduced cash burn provide a more stable financial position.

Next Steps

• Report final Phase 1 data for the breast cancer vaccine at the San Antonio Breast Cancer Symposium in December 2025.
• Initiate a Phase 2 clinical trial for the breast cancer vaccine in the neo-adjuvant setting, following final Phase 1 data release, FDA consultations, protocol development, manufacturing, and clinical site selection.
• Continue dose-escalation in the Phase 1 CAR-T therapy trial for ovarian cancer, with the study estimated to be completed in two to three years.
• Continue collaboration with Cleveland Clinic researchers to discover additional retired proteins for new vaccine targets in lung, colon, and prostate cancers.
• Potentially pursue additional at-the-market equity offerings to raise capital, with approximately $95 million remaining under the current program.

Key Dates

Recommendation

Anixa Biosciences shows promising clinical progress and improved financial management with reduced losses and operating expenses. The company has a runway of over 12 months with current cash. However, it remains a pre-revenue biotech, highly dependent on successful clinical outcomes and future licensing deals, which are inherently uncertain and long-term. While the clinical data is encouraging, the stock carries significant risk typical of early-stage biotechs. A 'hold' recommendation is appropriate for investors already in the stock, acknowledging the potential upside from clinical advancements against the backdrop of continued operational losses and the long path to commercialization. New investors might consider a 'hold' or 'neutral' stance, awaiting further de-risking through advanced clinical trial stages or concrete partnership announcements.

Keywords

Anixa Biosciences, ANIX, Biotechnology, Oncology, Cancer Vaccine, CAR-T Therapy, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer, Clinical Trials, Phase 1, Drug Development, SEC Filing, 10-Q, Financial Results, Research and Development, Liquidity, Biopharma